INTRODUCTION
============

Parkinson\'s disease (PD) is an age-related neurodegenerative disease with progressive loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). In patients, this depletion of neurons presents clinically with severe motor symptoms including uncontrollable resting tremor, bradikinesia, rigidity and postural imbalance ([@B30]; [@B31]; [@B34]). These symptoms, which affect 1% of individuals over the age of 65, start to manifest when 70\~80% of DA neurons in the SNpc are lost ([@B38]; [@B41]). The exact etiology of PD remains to be fully elucidated, but the key theories propose either an environmental (e.g. insecticides ([@B3]; [@B64]; [@B46])) or a genetic (e.g. parkin ([@B28])) origin, or a combination of both.

In 2009, the market value for PD and AD therapies exceeded US\$6.5 billion, ([@B63]) with projections that these will surpass cancer as the second most common cause of death of the elderly ([@B30]). Therefore, there is a real sense of urgency to discover novel therapies for the treatment or preferably, prevention of these diseases. Currently the only therapies approved for the treatment of PD and AD are agents that attenuate the symptoms (symptomatic) of the disease without disease modifying activity except the anti Parkinson drug rasagiline (Azilect) (Olanow et al., 2009), which we developed (Youdim et al., 2005). The mainstay for PD treatment focuses on the replacement of lost DA with L-dopa, dopamine (DA) agonists, monoamine oxidase B inhibitors and catechol-O-methyl tranferase inhibitors, thereby normalizing the patient symptomatically ([@B63]). While for AD there are the cholinesterase inhibitors and the glutamate antagonist memantine. Tragically, but important in view of the seriousness of disease progression, is the fact that the course of the disease is not affected by the utilization of these drugs, and the loss of neurons continues unabated even as symptoms may be controlled, at least following initial treatment. Currently, no drugs with claimed neuroprotective activity have been approved by the FDA for the treatment of PD or AD ([Table 1](#T1){ref-type="table"}) ([@B38]; [@B67]). Significantly though, recent research has suggested that some drugs used for symptomatic relief in PD, such as Azilect, pramipexole ([@B18]; [@B7]; [@B50]) and memantine ([@B58]; [@B51]) may also possess neuroprotective activities, rasagiline is currently only drug that may have a disease modifying activity (Olanow et al., 2009).

Recent literature show that there has been a paradigm shift in the way researchers are considering the development and design of drugs to treat diseases with complex etiological pathways (i.e. diseases with multiple drug targets) ([@B44]; [@B9]; [@B43]; [@B77]; [@B78]; [@B68]; [@B69]; [@B83]). In a pathway system with a multitude of drug targets, a drug with a single-target mechanism of action cannot always compensate or correct a complex pathway, which suggests that a complex pathway disease should be treated 1) with a multitude of molecules, each acting on different pathways in the disease (polypharmacy), or 2) with one molecule that possesses promiscuous activity acting on different pathways (multiple mechanism drugs).

Polypharmacy ([Fig. 1](#F1){ref-type="fig"}) therefore, is the clinical practice of combining two or more medications in a patient\'s medication profile, with a view to treat one specific disease. For example, the combination use of salmeterol (a β2-adrenergic agonist) and fluticasone (a glucocorticoid steroid) in asthma, has led to the combination of these two medications in one (Advair®). Also, the combination (in Vytorin®) of simvastatin (an HMG-CoA reductase inhibitor) and ezetimibe (an inhibitor of dietary cholesterol uptake) is used to treat hyperlipidemia ([@B83]). The major dilemma encountered in a polypharmaceutical approach, is a significant chance increase in side effects, which may be reduced statistically with the use of only one compound. The recent appearance on the market of drugs that display two mechanisms to treat a particular disease has been a clear move in the direction of the latter paradigm. One example, duloxetine (Cymbalta®), used in the treatment of depression, inhibits both serotonin and norepinepherine uptake in the central nervous system (CNS) ([@B75]; [@B26]; [@B14]). The introduction of drugs such as duloxetine indicates the clinical feasibility of designing multi-functional ligands to treat CNS disorders with complex disease pathways.

In this review, we will consider examples of compounds with multi-functional neuroprotective-neurorescue ([Table 1](#T1){ref-type="table"} for definitions) properties that may have promise in the treatment of PD and similar approaches have been made for multimodal drugs for AD (Youdim et al., 2006; Zheng et al., 2009), but for the present discussion we shall focus on PD only. Some of the compounds discussed were discovered through serendipity while others were the products of active drug design projects.

Rasagiline
----------

Rasagiline is a newly approved compound for the treatment of PD ([Fig. 2](#F2){ref-type="fig"}; [@B63]). Rasagiline (*N*-propargyl-1*R*-aminoindan) is an anti-PD drug with selective MAO-B inhibitory activity ([@B76]). Its *S* isomer, TV1022 (*N*-propargyl-1*S*-aminoindan), is more than a 1,000 times less potent as an MAO inhibitor than rasagiline, but still retains neuroprotective activity, which suggests that the propargylamine moiety (even when ostensibly not involved in Michael chemistry at the FAD within the MAO catalytic site as the processing group in suicide inhibition) is responsible for the neuroprotective activity seen in both these compounds ([@B72]; [@B2]; [@B79]; [@B81]).

The selectivity of rasagiline as an MAO-B inhibitor compared with TVP-1022, is thought to be associated with the ability of rasagiline to enter the catalytic site gorge of MAO-B. On the other hand, the configuration of the S-isomer imparts a highly restrictive conformation on the enzyme-ligand complex, which prevents the molecule from entering the catalytic site, precluding it from acting as a mechanism-based inhibitor. Interestingly, the neuroprotective activity associated with these compounds has now been shown to be associated with the ability of propargylamine ([@B72]; [@B2]) to protect mitochondrial viability by activation of Bcl-2 and protein kinase C (PKC)α and ε, and by down regulating proapoptotic FAS and Bax, and PKCδ and -γ ([@B76]). Additionally, these drugs induce the release of the soluble neuroprotective-neurotrophic form of the amyloid precursor protein α (sAPPα) through a PCK-MAP mediated activation of α-secretase ([@B78]).

The identification of the propargylamine moiety as a key element that confers neuroprotective activity and, in cases such as rasagiline and selegiline, also MAO inhibitory activity, led to the development of AchE inhibitors such as ladostigil (TV3326, now in phase II clinical studies), another anti-Alzheimer (AD)/anti-PD/antidepressant drug ([@B66]; [@B74]; [@B76]; [@B78]). Ladostigil ([Fig. 3](#F3){ref-type="fig"}) is a dual acetylcholine-butyrylcholine-esterase, and brain-selective MAO-A/B inhibitor *in vivo*, designed by combining the carbamate cholinesterase inhibitory moiety found in the rivastigmine molecule, with the pharmacophore of rasagiline and TVP1022 both of which possess the propargylamine moiety. Ladostigil has been shown to have antidepressant activity due to its ability to inhibit MAO-A in the raphe nucleus, striatum, hippocampus, and hypothalamus, and to raise brain levels of DA, norepinephrine, and serotonin ([@B74]). Its ability to also inhibit MAO-B attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity in mice, a rodent model of parkinsonism ([@B60]). Although a poor MAO-B inhibitor, the S isomer of ladostigil, TV3279, has shown similar neuroprotective activity to rasagiline and ladostigil *in vitro* and in laboratory animals ([@B78]), with molecular mechanisms apparently identical to that of rasagiline.

Iron chelators with radical scavenging and brain-selective monoamine oxidase inhibitory activity
------------------------------------------------------------------------------------------------

Degenerating nigrostriatal DA neurons are the main pathological feature in the SNpc of PD sufferers. In addition, many PD patients also experience dementia and depression that likely result from sporadic neurodegeneration in cholinergic, noradrenergic, and serotonergic pathways. In PD, accumulation of iron is found inside some melanin-containing DA-ergic neurons and inside amyloid plaques and neurofibrillary tangles associated with PD dementia ([@B80]). It has been suggested that iron accumulation may contribute to the oxidative stress-induced apoptosis reported in both PD and PD dementia ([@B80]; [@B79]). Such oxidative stress may result from increased glial monoamine oxidase (MAO) activity leading to exacerbated hydrogen peroxide production that can generate reactive hydroxyl radical through Fenton chemistry with intracellular ferrous iron. Iron chelators such as desferoxamine, clioquinol and VK-28 have been shown to have neuroprotective activity in animal models of AD and PD ([@B80]).

Based on this proposal, Zheng et al. ([@B82]) developed neuroprotective compounds with dual iron chelating and MAO-B inhibitory activity. These authors combined the antioxidant chelator moiety present in an 8-hydroxyquinoline derivative of the neuroprotective brain-permeable iron chelator VK-28, with the propargylamine moiety (found in compounds such as rasagiline and selegiline, as stated earlier). HLA20 was identified as a potential lead compound for further studies having selectivity for MAO-B with an IC~50~ value in the region of 110µM ([Fig. 4](#F4){ref-type="fig"}; \>200µM for MAO-A), as well as acting as a free radical scavenger. However, a related compound designated M30, unlike HLA20 was found *in vitro*, to be a highly potent MAO-A and B inhibitor with brain selectivity for these enzymes *in vivo*, in addition to possessing iron chelating properties similar to desferoxamine ([@B9]; [@B81]; [@B82]). M30 behaves similarly to other propargylamine MAO inhibitors by acting as a suicide- or mechanism-based inhibitor after being identified and processed as a substrate by the enzyme and imparts similar neuroprotective properties as those found in rasagiline and ladostigil ([Fig. 5](#F5){ref-type="fig"}). M30 protects against MPTP and kainate neurotoxicity in mice by virtue of both its MAO inhibitory and iron chelating/radical scavenging properties in these two animal models of neurodegeneration. It has recently been shown to have dopaminergic neurorestorative activity in post treatment with MPTP (Gal et al., 2009) and lactacystin (Zhu et al., 2007) models of PD. The neurogenic activity of M30 and HLA-20 has been attributed to the inhibition of iron dependent prolyl-4-hydroxylase, via chelation of iron and activation of HIF (hypoxia inducing factor) that regulates transcription of a series of neurotropins such as BDNF, GDNF, erythropoietin and VEGF. The Consequence of HIF activation is inhibition of cell cycle G^0^/G^1^, that results in inhibition of cyclin D1 that causes cell arrest differentiation into neurons as seen in the neurorestorative activity of M30 in the two models of PD (Zhu et al., 2007; Gal et al., 2009; Kupershmidt et al., 2009).

For AD therapeutics we have introduced a carbamate cholinesterase inhibitor (ChEI) moieties into M30, such as M30C-N and into HLA-20 to give HLA-20A and have even added the glutamate antagonist, memantine, which is presently in the clinical use. These compounds HLA-20A ([Fig. 6](#F6){ref-type="fig"}) and M30C-N ([Fig. 7](#F7){ref-type="fig"}) have been shown to have potent ChE I and MAO-A and B inhibitory activity and possess similar neuroprotective activity to those of their parent compounds, HLA-20 and M30 (Zheng et al., 2009).

The accumulation of iron at sites where neurons degenerate in PD, is thought to be a major event that is linked to the neurodegenerative process ([@B80]). The novel non-toxic lipophilic (and therefore brain-permeable) iron chelator VK-28, and its multi-functional derivative, M30 (both of which possess the MAO inhibitory and neuroprotective propargyl moiety of rasagiline), offer potential therapeutic benefits for PD. M30 attenuates apoptotic events in SH-SY5Y neuroblastoma cells in a serum deprivation model via multiple protection mechanisms, including 1) reduction of the pro-apoptotic proteins, Bad and Bax; 2) reduction of apoptosis-associated Ser139-phosphorylated H2A.X; 3) induction of the anti-apoptotic protein, Bcl-2 and 4) inhibition of the cleavage and activation of caspase-3. M30 also promotes morphological changes, resulting in axonal growth-associated protein-43 (GAP-43), which is implicated in neuronal differentiation. The compound markedly reduces the levels of cellular holo-APP, the β-C-terminal fragment (β-CTF), and levels of amyloidogenic Aβ peptide in the medium of SH-SY5Y and CHO cells stably transfected with the APP \"Swedish\" mutation. In addition, levels of the nonamyloidogenic sAPPα in cell medium, as well as levels of α-CTF in cell lysate were found to be elevated. These results are consistent with the presence of an iron-responsive element (IRE) in the 5\'-untranslated region (5\'UTR) of APP and demonstrate the effectiveness of M30 in limiting holo-APP expression and Aβ peptide secretion. Therefore, the multifunctional properties of M30 suggest that it may offer extraordinary potential as a drug for the treatment of PD, especially PD dementia ([@B1]) and AD (Mandel et al., 2007; Amit et al., 2008) and more recently in transgenic G93A SOD model of ALS (amyotrophic lateral sclerosis) where it extends the life span of these animals and has neurogenic activity in NCS-34 rat motor neurons (Kupershmidt et al., 2009).

Monoamine oxidase inhibition by A~2A~ receptor antagonists
----------------------------------------------------------

In PD, a dual mechanism that includes inhibition of MAO-B, as well as adenosine A~2A~ receptor blockade offer a novel therapeutic approach to prevent neuronal cell death ([Fig. 9](#F9){ref-type="fig"}). As detailed earlier, MAO-B plays a role in the catabolism of neurotransmitters such as DA, serotonin and norepinephrine, leading to hydrogen peroxide formation which contributes to oxidative stress and neuronal cell death ([@B57]). Levels of MAO-B are found to be increased in older patients ([@B62]; [@B61]; [@B35]) which has led to the rationale for the use of drugs such as selegiline (deprenyl) and lazabemide, ([@B65]) and the design of drugs such as ladostigil, ([@B78]) as described before.

Caffeine, a non-selective adenosine receptor antagonist, is under some scrutiny as a potential drug to counteract age-related cognitive decline ([Fig. 8](#F8){ref-type="fig"}). Work in this regard is supported by evidence that critical changes in adenosine-related neurotransmission occur with aging and may be counteracted by adenosine receptor antagonists ([@B36]; [@B6]; [@B52]). Caffeine, in fact, has been suggested to protect against β-amyloid neurotoxicity, ([@B6]) while acute treatment with caffeine and the A~2A~ receptor antagonist ZM241385 was recently found to reverse age-related olfactory deficits and memory decline in rats ([@B52]) clearly suggesting involvement of A~2A~, but not A~1~ receptors, in cognitive decline and possibly, neurodegenerative processes. Evidence such as the preceding, and other evidence for neuroprotection also in parkinsonian models, led Petzer et al. ([@B49]) to evaluate (*E*)-8-styrylxanthinyl derived adenosine A~2A~ receptor antagonists for inhibition also of brain MAO-B. Included in these studies were KW-6002, a potent A~2A~ receptor antagonist (Ki of 2.2 nM) which is undergoing clinical trials for PD, and (*E*)-8-(3-chlorostyryl)-caffeine (CSC; [Fig. 8](#F8){ref-type="fig"}), which has been shown to be neuroprotective in the MPTP parkinsonian mouse model ([@B5]). All of the compounds tested in the studies by Petzer et al. ([@B49]) showed MAO-B inhibition in the low micromolar to high nanomolar range, with the Ki of KW-6002 at 21µM, and that of CSC at 0.1µM. These results clearly suggest that the neuroprotective properties of KW-6002 and CSC may in part be due to MAO-B inhibition, in synergism with the A~2A~ antagonism ([@B4]).

NMDA antagonism by calcium channel blockers
-------------------------------------------

The divalent calcium cation plays an important role in neuronal cell death ([@B33]; [@B21]; [@B24]; [@B45]). One of the receptors activated by glutamate (together with its co-agonist glycine), the NMDA receptor, is a major conduit for the influx of calcium ions into cells under excitotoxic conditions. The prevention of such excessive influx of calcium (known as excitotoxicity) therefore remains a major drug target in the design of neuroprotective agents. Excess accumulation of calcium in neuronal cells rapidly leads to cell death through a variety of mechanisms including activation of proteases, nucleases, phospholipases, nitric oxide synthase (NOS), and other degradative enzymes that not only lead to activation of death cascades, but also to free radical formation ([@B33]). NMDA receptor antagonists such as dizocilpine (MK-801) and memantine may possess a dual mechanism by which neuronal cells are protected, both by direct blockade of the NMDA receptor and by attenuating TNFα-induced potentiation of glutamate toxicity ([@B84]).

Brain injury after ischemic stroke also triggers a release of glutamate-associated excitotoxic events, and the incidence of cognitive impairment and dementia have both been reported to be elevated after cerebral stroke, especially in the elderly ([@B23]). Up to 25% of stroke patients exhibit symptoms of dementia, including symptoms reminiscent of PD dementia ([@B71]). Stroke is the third leading cause of death in the United States ([@B45]) and there is a definitive need to develop drugs that can protect or save neurons after an ischemic incident since, to date, no effective treatment has been developed to prevent neuronal cells from dying during stroke conditions ([@B21]).

Several studies have shown that NMDA receptor antagonists, such as dizocilpine (MK-801) and the polycyclic cage amine memantine, display neuroprotective effects in experiments using ischemia paradigms in neurons ([@B15]; [@B21]; [@B13]; [@B56]). An alternative pathway for calcium to enter into neuronal cells is through voltage-gated ion channels, such as L-type calcium channels. Animal experiments with nimodipine have suggested that calcium channel antagonists may be neuroprotective in ischemia by antagonizing the influx of calcium into neuronal cells ([@B21]). The importance of calcium overload during cell death, suggests that a dual calcium channel and NMDA receptor antagonist might be useful as a neuroprotective drug in stroke and other neurodegenerative disease such as idiopathic PD, where it has been suggested that brain-permeable L-type calcium channel blockers may have a salutary effect on the disease.

NGP1-01 (8-benzylamino-8,11-oxapentacycloundecane) is a polycyclic cage amine derived from the reductive amination of benzylamine and Cookson\'s \"bird cage\" diketone of which the biology was first described by Van der Schyf ([@B70]) ([Fig. 10](#F10){ref-type="fig"}). The L-type calcium channel blocking activity of NGP1-01 was investigated utilizing electrophysiological experiments in isolated guineapig papillary muscle and sheep Purkinje fibers ([@B70]). The structural similarity of NGP1-01 to another polycyclic cage amine and NMDA receptor antagonist, memantine, led to the evaluation of NGP1-01 for potential NMDA receptor antagonism. Memantine is an uncompetitive NMDA receptor antagonist which is used clinically to treat AD, but has also been used for PD in Germany ([@B47]; [@B58]; [@B51]). Its favorable fast on-off binding kinetics gives this compound an improved side effect profile compared with other NMDA antagonists such as MK-801 ([@B47]). NGP1-01 was shown to also be an uncompetitive NMDA antagonist in murine whole brain synaptoneurosomes and blocked NMDA-mediated ^45^Ca^2+^ uptake with an IC~50~ of 2.98µM ([@B10]).

In a recent paper Kiewert et al. ([@B25]) showed that NGP1-01 (at 1µM) inhibited depolarizationinduced calcium influx by 78% in cortical neurons preloaded with fura-2 AM, with a potency similar to that of nimodipine, while simultaneously inhibiting NMDA-induced (1 mM) calcium influx by 52%, only slightly less potent than memantine. Using *in vivo*-microdialysis, choline release was monitored during NMDA infusion as a measure of excitotoxic membrane breakdown. Intraperitoneal injection of NGP1-01 (40 mg/kg) reduced NMDA-induced membrane breakdown by 31% (p\<0.01) while memantine (10 mg/kg) reduced choline release by 40%. These results demonstrate that NGP1-01 simultaneously blocks both major neuronal calcium channels and is brain-permeable after peripheral administration. This dual mechanism of modulating calcium entry into neuronal cells might suggest that NGP1-01 may have utility as a neuroprotective agent in PD, stroke and other neurodegenerative diseases, especially in patients with comorbidity among these diseases. This promise of neuroprotection has recently been partly confirmed in *in vivo* studies using the middle cerebral artery occlusion (MCAO) mouse model of stroke, wherein it was shown that NGP1-01, administered 30 minutes before MCAO, afforded substantial protection against cerebral ischemia-induced brain lesioning, as well as brain swelling measured 24 hours after MCAO ([@B40]).

Another role assigned to cage amines such as NGP1-01 in PD therapy is the ability of these compounds to inhibit DA re-uptake into nerve terminals ([Fig. 10](#F10){ref-type="fig"}). Compounds that are able to block the DA transporter (DAT) have been suggested to be more useful in treating the motor symptoms in PD, as opposed to norepinephrine and serotonin re-uptake inhibitors ([@B19]). Additionally, compounds with the ability to block DAT, may also have neuroprotective activity ([@B27]). NGP1-01 was recently shown to block DA re-uptake in murine synaptosomes with an IC~50~ of 57µM. One of NGP1-01\'s derivatives, a phenylethylamine derivative, was even more potent with an IC~50~ of 23µM ([@B11]). The latter compound was also found to be neuroprotective in the MPTP-parkinsonian mouse model, affording protection against a single 35 mg/kg (ip) dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) ([@B12]).

Green tea polyphenols
---------------------

Polyphenols are natural products present in beverages such as red wine and tea ([@B73]). One of the classes of polyphenols which are pharmaceutically interesting is the flavenoids ([Fig. 11](#F11){ref-type="fig"}). These compounds are characterized by an aromatic ring which is condensed to a heterocyclic ring and attached to a second aromatic ring. An innovative therapeutic approach could be the use of natural plant polyphenol flavonoids, reported to have access to the brain and to possess multifunctional activities as iron chelators, radical scavengers, anti-inflammatory agents and neuroprotectants ([@B42]; [@B17]; [@B20]; [@B22]).

These compounds and their actions have been extensively reviewed ([@B39]). In particular, the major constituent of green tea catechin extract (-)-epigallocatechin-3-gallate (EGCG; [Fig. 11](#F11){ref-type="fig"}) plays a major role in the prevention of neurodegeneration in a variety of cellular and animal models of neurodegenerative diseases ([@B37]). This effect appears to be mediated through multiple pathways, including the participation of the pro-survival PKC and extracellular mitogen-activated protein kinase (MAPK) signaling and the promotion of neurite outgrowth ([@B54]). Structurally important features defining their chelating potential are the 3\',4\'-dihydroxyl group in the B ring ([@B20]), as well as the gallate group ([@B29]) which may neutralize ferric iron to form redox-inactive iron, thereby protecting cells against oxidative damage ([@B16]). Recent studies have shown that prolonged administration of EGCG to mice induced a significant reduction in membrane-associated APP levels in hippocampus ([@B32]) and in cerebral Aβ levels concomitant with reduced β-amyloid plaques ([@B53]). This effect may be accounted for, in part, by the chelation of the intracellular free-iron labile pool, modulating APP mRNA translation via its IRE-type II ([@B55]), as has recently been described for other metal chelators, such as desferoxamine, clioquinol and dimercaptopropanol ([@B48]; [@B59]).

DISCUSSION
==========

PD and AD are complex diseases with multiple pathways which contribute to its etiology and finally cell death of DA-ergic, cholinergic and other neurons. To address this multiplicity, compounds that target more than one drug target in the cell death cascades are now investigated and designed. The feasibility of moving these drugs to market has been shown through the success of rasagiline, which has been shown to have neuroprotective activity and has made it to the market as a PD therapeutic (Olanow et al., 2009). The development of multimodal drugs is not limited to neurodegenerative disease, but rather that similar approaches are under way with other complex disease such as cancer, AIDS, depressive illness, schizophrenia and possibly cardiovascular disorders (Youdim and Van der Schyf, 2009).
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